These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 20360295)

  • 1. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
    Jacobson TA
    Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
    Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism and mitigation of niacin-induced flushing.
    Kamanna VS; Ganji SH; Kashyap ML
    Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
    Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB
    Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin use and cutaneous flushing: mechanisms and strategies for prevention.
    Davidson MH
    Am J Cardiol; 2008 Apr; 101(8A):14B-19B. PubMed ID: 18375236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation.
    Cefali EA; Simmons PD; Stanek EJ; Shamp TR
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):633-40. PubMed ID: 17190373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
    Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
    J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of extended-release niacin with laropiprant.
    Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
    Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
    Thakkar RB; Kashyap ML; Lewin AJ; Krause SL; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2009; 9(2):69-79. PubMed ID: 19331435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin, an old drug with new perspectives for the management of dyslipidaemia.
    Benhalima K; Muls E
    Acta Clin Belg; 2010; 65(1):23-8. PubMed ID: 20373594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation.
    Cefali EA; Simmons PD; Stanek EJ; McGovern ME; Kissling CJ
    Int J Clin Pharmacol Ther; 2007 Feb; 45(2):78-88. PubMed ID: 17323787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
    Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
    Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avoid no-flush niacin in favor of the prescription version. Follow certain steps to reduce the flushing effects of prescription niacin.
    Heart Advis; 2010 Nov; 13(11):5. PubMed ID: 22834056
    [No Abstract]   [Full Text] [Related]  

  • 16. Niacin-a critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular disease.
    Mason CM; Doneen AL
    J Cardiovasc Nurs; 2012; 27(4):303-16. PubMed ID: 21804401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy.
    Kawata AK; Revicki DA; Thakkar R; Jiang P; Krause S; Davidson MH; Punzi HA; Padley RJ
    Clin Drug Investig; 2009; 29(4):215-29. PubMed ID: 19301936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niacin: its value in raising HDL cholesterol is being questioned.
    Heart Advis; 2011 Oct; 14(10):7. PubMed ID: 23019714
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
    McKenney JM
    Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.